WANY
ACXP icon

Wealthspire Advisors (New York)’s Acurx Pharmaceuticals ACXP Stock Holding History

Wealthspire Advisors (New York)’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15
Closed -$65 – 1055
2025
Q3 		$65 Buy
+15
New +$90 ﹤0.01% 3017

Other funds holding ACXP

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Wealthspire Advisors (New York)'s ACXP Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Acurx Pharmaceuticals (ACXP) in Q4 2025, closing a stake of 15 shares — an estimated $65 sold.

Wealthspire Advisors (New York) first reported a position in ACXP in Q3 2025 and held it in 1 quarter. The position peaked at $65 in Q3 2025. 18 funds tracked by Wall St. Rank hold ACXP as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Acurx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 15 Acurx Pharmaceuticals shares in Q4 2025, an estimated $65.
  • Wealthspire Advisors (New York) first reported a position in Acurx Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Acurx Pharmaceuticals position peaked at $65 in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.